RxDoctor Payments Data

Joseph Rinaldi

Nurse Practitioner · Ronceverte, WVNPI 1417387390

Payments from drug & device makers

$761in general payments, 2019–2025

Across 34 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$260
  • AstraZeneca$230
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$85
  • Otsuka America Pharmaceutical, Inc.$57
  • Lilly USA, LLC$41
  • Novo Nordisk$36
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$761100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$761 in reported general payments places this provider in the 75th percentile of 649 nurse practitioner providers in West Virginia.

See all nurse practitioner providers in West Virginia

Medicare billing

Part B allowed, 2024
$19,163
Medicare patients
191
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban67$57,663
EntrestoSacubitril/Valsartan23$21,633
XareltoRivaroxaban12$17,356
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,875
SymbicortBudesonide/Formoterol Fumarate16$4,818
Flecainide Acetate45$1,061
Albuterol Sulfate HfaAlbuterol Sulfate33$1,031
Atorvastatin Calcium66$579
Hydroxyzine Hcl13$554
Metoprolol Tartrate58$478
Metoprolol Succinate52$457
Bisoprolol Fumarate29$380
Cefdinir25$364
Doxycycline Monohydrate27$330
Ondansetron OdtOndansetron27$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort$230$4,81816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 649 nurse practitioner providers in West Virginia.

Other nurse practitioner in Ronceverte

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →